title: The GP2 peptide: a HER2/neu-based breast cancer vaccine.
abstract: Preclinical studies suggest that GP2, a HER2/neu-derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2-based vaccines are safe and effective in stimulating peptide-specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2-based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab.
authors.affiliation: Department of Surgery, General Surgery Service, Brooke Army Medical Center, Ft. Sam Houston, Texas, USA.
authors.forename: Kevin S
authors.initials: KS
authors.lastname: Clive
authors.forename: Josh A
authors.initials: JA
authors.lastname: Tyler
authors.forename: G Travis
authors.initials: GT
authors.lastname: Clifton
authors.forename: Jarrod P
authors.initials: JP
authors.lastname: Holmes
authors.forename: Sathibalan
authors.initials: S
authors.lastname: Ponniah
authors.forename: George E
authors.initials: GE
authors.lastname: Peoples
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Mittendorf
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000276:immunology* / Q000517:prevention & control*; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology*; D002986:Clinical Trials as Topic; D019281:Dimerization; D005260:Female; D058851:GPI-Linked Proteins / Q000009:adverse effects / Q000276:immunology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D015789:HLA-A2 Antigen / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007167:Immunotherapy / Q000379:methods; D018396:Mucin-1 / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology / Q000378:metabolism*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D058851:GPI-Linked Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D015789:HLA-A2 Antigen; D007074:Immunoglobulin G; D018396:Mucin-1; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C489339:GP2 protein, human; C520326:MUC-1 protein, human (950-958)